Navigation Links
Bioniche Secures Final Financing to Scale-up E. coli O157:H7 Vaccine Production
Date:6/25/2008

- full $25 million of required financing now in place -

BELLEVILLE, ON, June 25 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that it has secured an amendment to a pre-existing $7.6 million contribution agreement with the Industrial Technologies Office of Industry Canada that will support the scale-up of its vaccine production facility in Belleville, Ontario. The amended agreement extends the timeline for completion of work on the production scale-up to March 31, 2013.

This funding will be combined with the $10 million in Ontario government financing through the Ministry of Economic Development and Trade (MEDT)'s Advanced Manufacturing Investment Strategy (AMIS), $5 million in federal government financing through the Agri-Opportunities Program of the Department of Agriculture and Agri-Food (Canada) (AAFC), both announced in December, 2007, and a loan of $5 million from the Business Development Bank of Canada (BDC) announced in February, 2008. With $25 million in funding now in place, the Company has the required financing to complete the scale-up of vaccine production at its Belleville facility over the next two years. This will provide capacity of a minimum of 40 million doses of the E. coli O157:H7 vaccine. It is part of a long-term, $107 million project to create a state-of-the-art Animal Health and Food Safety Vaccine Manufacturing Centre in Belleville.

"We are pleased to have all of the necessary financing now in place to complete the first phase of production scale-up in Belleville," said Graeme McRae, President & CEO of Bioniche Life Sciences Inc. "The assistance of these programs has provided a favourable weighted average cost of capital and the terms of the funding will permit repayment from vaccine revenues. The fact that the majority of this financing is coming from various levels of government demonstrates recogniti
'/>"/>

SOURCE Bioniche Life Sciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Bioniche Responds to Australian Equine Influenza Outbreak
2. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
3. Bioniche Food Safety Vaccine Receives Global Top Honours in Industry Excellence Awards
4. Bioniche Receives Comment from USDA on a Field Trial for E. coli O157:H7 Cattle Vaccine
5. Media Advisory - Bioniche Discusses USDA Comment on E. coli O157:H7 Cattle Vaccine Field Trial
6. Bioniche to Present at Rodman & Renshaw 9th Annual Healthcare Conference
7. Bioniche Reports Fiscal 2008 First Quarter
8. Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario
9. Bioniche Amends Terms of Convertible Debt with Laurus Master Funds
10. USDA Agrees to Grant Conditional License to Bioniche for its E. coli O157:H7 Cattle Vaccine
11. Bioniche Reports Fiscal 2008 Second Quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 01, 2015 , ... ... (NAPBS®) has announced that Edge Information Management has been granted continued ... Screening Credentialing Council (BSCC). , “Achieving and maintaining this accreditation takes ...
(Date:9/1/2015)... ... 2015 , ... With former IBMers among its founding members, Inmar has known ... than 35 years ago. A pilot program begun by the company in 2014 has ... those intent on pursuing careers in these fields. The program is now open to ...
(Date:9/1/2015)... ... September 01, 2015 , ... Royal River Natural Foods, a ... followed men and women for 19 years and found that, among those who had ... multivitamins. , The report is part of the September 2015 issue of “Natural Insights ...
(Date:9/1/2015)... ... September 01, 2015 , ... The FSH Society , the ... muscular dystrophy (FSHD), will be the beneficiary of a collection of fundraising events this ... raise awareness of the FSH Society and further FSHD research. , The ...
(Date:9/1/2015)... , ... September 01, 2015 , ... SC&H Group, a ... which includes being named a “Best of the Best” firm in the U.S., as ... named the “Best of the Best” in the U.S., selected exclusively on performance in ...
Breaking Medicine News(10 mins):Health News:Edge Information Management Granted Continued NAPBS Accreditation 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 3Health News:Inmar Announces Program to Fuel Student Passion for STEM – with an Unconventional Twist 2Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 3Health News:SC&H Group Receives Multiple Honors from INSIDE Public Accounting 2
... A new study by researchers at the University of British ... , The study, published in the Journal of Public ... are three times more likely than those who don,t to ... minimum of physical activity. , Doctoral student Ugo Lachapelle and ...
... YORK, March 26 California has one of ... As more people become,uninsured due to the ... of programs that helps people without prescription coverage,save ... Hispanics about,how to access necessary medications. During "Cover ...
... The Susan G. Komen for the Cure(R) Advocacy ... (D-MA) and Kay Bailey Hutchison (R-TX) to reignite the ... 21st Century Cancer ALERT ( A ccess to ... and T reatment) Act. (Logo: ...
... March 26 Methodist Hospital in Houston has ... to settle allegations that it defrauded the federal ... resolves allegations that Methodist improperly increased charges to ... from Medicare. In addition to its standard ...
... part of government strategy to tackle issue , , ... U.S. rivers were found to be tainted with traces ... study from the U.S. Environmental Protection Agency and Baylor ... and two types of antidepressants were among the seven ...
... 2009 Two University of Rhode Island scientists have revealed ... species (ROS) -- a type of stress signal. Their findings ... human cells and may help in the design of drugs ... Professor Gongqin Sun in the URI Department of Cell and ...
Cached Medicine News:Health News:Public transit users 3 times more likely to meet fitness guidelines: UBC research 2Health News:As the Number of Unemployed Grows, Pfizer Helpful Answers and SABEResPODER Join Forces to Educate Hispanics Who Lack Health Insurance About How to Access Prescription Medicines 2Health News:As the Number of Unemployed Grows, Pfizer Helpful Answers and SABEResPODER Join Forces to Educate Hispanics Who Lack Health Insurance About How to Access Prescription Medicines 3Health News:Susan G. Komen for the Cure(R) Advocacy Alliance Applauds Senators Kennedy, Hutchison for Bipartisan Cancer Alert Act 2Health News:Houston's Methodist Hospital to Pay U.S. More Than $9 Million to Resolve Allegations of Overcharging Medicare 2Health News:Fish in U.S. Rivers Tainted With Common Medications 2Health News:URI scientists reveal mechanism that regulates cancer-causing gene 2
(Date:9/1/2015)... 1, 2015  Amgen (NASDAQ: AMGN ) ... the areas of Alzheimer,s disease and migraine. The ... by teaming up with Novartis on a differentiated ... genetically predisposed individuals at risk of developing Alzheimer,s ... the commercialization of its migraine programs in the ...
(Date:9/1/2015)... 1, 2015 Nevro Corp. (NYSE: NVRO ... innovative evidence-based solutions for the treatment of chronic pain, ... response to the Patent Trial and Appeals Board (PTAB) ... review (IPR), filed by a unit of Boston Scientific ... Patent No. 8,359,102 (the ,102 patent). The ,102 patent is ...
(Date:9/1/2015)... THOUSAND OAKS, Calif. and ... (NASDAQ: AMGN ) and UCB (Euronext Brussels: ... trial (STudy evaluating effect of RomosozUmab Compared with ... risk for fracture pReviously treated with bisphosphonatE therapy). ... a statistically significant difference in favor of romosozumab ...
Breaking Medicine Technology:Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 2Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 3Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 4Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 5Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 6Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 7Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 8Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 9Nevro Announces Submission of Preliminary Response to the Patent Trial and Appeals Board 2Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 2Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 3Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 4Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 5Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 6Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 7Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 8Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 9
... the community pharmacy chain, has revealed that one in four* (24%) ... - has taken or applied medicines which they later discovered were ... half (53%) of people do not always check the expiry date ... member. This is worrying considering that nearly one ...
... 4, 2011 Sanofi-aventis (EURONEXT: SAN and NYSE: ... exchange offer for all outstanding shares of common stock of ... and withdrawal rights expired at 11:59 p.m., New York City ... offer has advised sanofi-aventis that, as of the expiration time, ...
Cached Medicine Technology:Lloydspharmacy Reveals Over 11 Million Britons Risking Health by Taking Old Medicines 2Lloydspharmacy Reveals Over 11 Million Britons Risking Health by Taking Old Medicines 3Sanofi-aventis Successfully Completes Exchange Offer for Genzyme Corporation 2Sanofi-aventis Successfully Completes Exchange Offer for Genzyme Corporation 3Sanofi-aventis Successfully Completes Exchange Offer for Genzyme Corporation 4Sanofi-aventis Successfully Completes Exchange Offer for Genzyme Corporation 5Sanofi-aventis Successfully Completes Exchange Offer for Genzyme Corporation 6
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: